160 related articles for article (PubMed ID: 24955652)
21. Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution.
Mitra A; Nan A; Ghandehari H; McNeill E; Mulholland J; Line BR
Pharm Res; 2004 Jul; 21(7):1153-9. PubMed ID: 15290854
[TBL] [Abstract][Full Text] [Related]
22. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma.
Deutscher SL; Figueroa SD; Kumar SR
Nucl Med Biol; 2009 Feb; 36(2):137-46. PubMed ID: 19217525
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
24. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
25. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.
Ray A; Larson N; Pike DB; Grüner M; Naik S; Bauer H; Malugin A; Greish K; Ghandehari H
Mol Pharm; 2011 Aug; 8(4):1090-9. PubMed ID: 21599008
[TBL] [Abstract][Full Text] [Related]
26. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
27. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
28. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Liu J; Kopecková P; Bühler P; Wolf P; Pan H; Bauer H; Elsässer-Beile U; Kopecek J
Mol Pharm; 2009; 6(3):959-70. PubMed ID: 19344119
[TBL] [Abstract][Full Text] [Related]
29. Development of (G3-C12)-mediated camptothecin polymeric prodrug targeting to Galectin-3 receptor against androgen-independent prostate cancer.
Yuan X; Liu L; Wang W; Gao YR; Zhang D; Jia TT; Zeng HR; Pan G; Yuan Y
Int J Pharm; 2020 Apr; 580():119123. PubMed ID: 32035258
[TBL] [Abstract][Full Text] [Related]
30. Galactosylated N-2-hydroxypropyl methacrylamide-b-N-3-guanidinopropyl methacrylamide block copolymers as hepatocyte-targeting gene carriers.
Qin Z; Liu W; Li L; Guo L; Yao C; Li X
Bioconjug Chem; 2011 Aug; 22(8):1503-12. PubMed ID: 21688826
[TBL] [Abstract][Full Text] [Related]
31. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.
Newton-Northup JR; Dickerson MT; Ma L; Besch-Williford CL; Deutscher SL
Clin Exp Metastasis; 2013 Feb; 30(2):119-32. PubMed ID: 22851004
[TBL] [Abstract][Full Text] [Related]
33. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution.
Chytil P; Hoffmann S; Schindler L; Kostka L; Ulbrich K; Caysa H; Mueller T; Mäder K; Etrych T
J Control Release; 2013 Dec; 172(2):504-12. PubMed ID: 23697767
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization.
Zaiden M; Feinshtein V; David A
J Control Release; 2017 Jul; 257():10-20. PubMed ID: 28093296
[TBL] [Abstract][Full Text] [Related]
35. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.
Buckway B; Frazier N; Gormley AJ; Ray A; Ghandehari H
Nucl Med Biol; 2014 Mar; 41(3):282-9. PubMed ID: 24461626
[TBL] [Abstract][Full Text] [Related]
36. Molecular imaging of HPMA copolymers: visualizing drug delivery in cell, mouse and man.
Lu ZR
Adv Drug Deliv Rev; 2010 Feb; 62(2):246-57. PubMed ID: 20060431
[TBL] [Abstract][Full Text] [Related]
37. Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics.
Liu J; Bauer H; Callahan J; Kopecková P; Pan H; Kopecek J
J Control Release; 2010 Apr; 143(1):71-9. PubMed ID: 20043962
[TBL] [Abstract][Full Text] [Related]
38. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
Lammers T
Adv Drug Deliv Rev; 2010 Feb; 62(2):203-30. PubMed ID: 19951732
[TBL] [Abstract][Full Text] [Related]
39. Endocytotic uptake of HPMA-based polymers by different cancer cells: impact of extracellular acidosis and hypoxia.
Gündel D; Allmeroth M; Reime S; Zentel R; Thews O
Int J Nanomedicine; 2017; 12():5571-5584. PubMed ID: 28831253
[TBL] [Abstract][Full Text] [Related]
40. Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA.
Kissel M; Peschke P; Subr V; Ulbrich K; Strunz AM; Kühnlein R; Debus J; Friedrich E
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1055-62. PubMed ID: 12173020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
